CJC-1295 No DAC (Mod GRF 1-29)
Worth trying, BioHarmony verdict
BioHarmony score 5.8 out of 10
CJC-1295 No DAC (Mod GRF 1-29) is a short-acting GHRH peptide, almost always stacked with ipamorelin, that prompts a pulse of your own growth hormone. Human data exists only for the long-acting DAC version, per Teichman 2006; the no-DAC form has no dedicated human trial, and neither form has a human outcome study.
Read full reportWhat is CJC-1295 No DAC (Mod GRF 1-29)?
CJC-1295 No DAC, better known as Mod GRF 1-29, is a lab-made peptide that nudges your own pituitary to release a short pulse of growth hormone, and the "No DAC" part is the whole point. It activates the growth-hormone-releasing-hormone receptor, then clears in about 30 minutes, so it mimics the brief, natural rise and fall your body produces on its own. That is the version people stack with ipamorelin. Its long-acting sibling, CJC-1295 with DAC, binds to albumin and keeps growth hormone elevated for 6 to 8 days, a sustained "bleed" most experienced users avoid as non-physiological.
From the BioHarmony report, reviewed Sep 19, 2026.
Saved on this device only.
Safety watch-outs
- Worsening or progressive reaction with each injection (possible sensitization): stop immediately.
- New or worsening numbness or tingling (possible fluid-related nerve compression): reduce dose or stop.
- Rising fasting glucose or HbA1c: stop and consult a clinician, especially with diabetes.
- Any active or suspected cancer: do not use
- growth-hormone-axis stimulation is contraindicated.
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for CJC-1295 No DAC (Mod GRF 1-29) yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (2)
Attributed viewpoints, separate from primary research.
- International Peptide Society 2018 Compound Curriculum Dr. William Seeds,
- Mod GRF 1-29 vs Sermorelin: Full Comparison Guide Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA identifies immunogenicity and peptide-impurity concerns for compounded CJC-1295 and reports limited clinical data plus serious adverse events.
Primary sources
- Certain bulk drug substances for use in compounding that may present significant safety risks U.S. Food and Drug Administration,
Related peptides for recovery & tissue repair
- 7.4Thymosin Alpha-1Thymosin Alpha-1 is a 28-amino-acid thymic peptide with strongest evidence in immune-compromised and hospital-adjacent settings: Cao 2024 pooled 39 acute COPD…
- 7.2GHK-Cu (Copper Peptide)GHK-Cu is a human copper-binding tripeptide with the best evidence for topical skin repair and wound healing, including Mulder 1994 diabetic ulcer data showing 98.5%…
- 7.1SemaxSemax is a Russian-developed ACTH 4-7 + PGP heptapeptide with the strongest human signal in post-stroke recovery, including a 110-patient Gusev et al.
- 6.9Thymosin Beta-4 (Full)Thymosin beta-4 is the native 43-amino-acid peptide that promotes tissue repair via actin-sequestering and the Ac-SDKP repair axis.
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.